AstraZeneca PLC provided earnings guidance for the fiscal year 2022. The company expects total revenue to increase by a high teens percentage and Core EPS is expected to increase by a mid-to-high twenties percentage.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,348 GBX | +0.68% | +1.50% | +16.40% |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.40% | 238B | |
+32.96% | 698B | |
+26.51% | 568B | |
-4.35% | 358B | |
+19.14% | 328B | |
+3.85% | 283B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.30% | 165B | |
-4.06% | 160B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca PLC Provides Earnings Guidance for the Fiscal Year 2022